Dose rate correction in medium dose rate brachytherapy for carcinoma cervix

Purpose: To establish the magnitude of brachytherapy dose reduction required for stage IIB and III carcinoma cervix patients treated by external radiation and medium dose rate (MDR) brachytherapy at a dose rate of 220±10 cGy/h at point A. Materials and methods: In study-I, at the time of MDR brachyt...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 1998-12, Vol.49 (3), p.317-323
Main Authors: Patel, Firuza D, Negi, Pritam S, Sharma, Suresh C, Kapoor, Rakesh, Singh, Deepinder P, Ghoshal, Sushmita
Format: Article
Language:English
Subjects:
Brachytherapy
Carcinoma cervix
Carcinoma, Squamous Cell - pathology
Carcinoma, Squamous Cell - radiotherapy
Cobalt Radioisotopes - therapeutic use
Disease-Free Survival
Dose-Response Relationship, Radiation
Female
Follow-Up Studies
Humans
Incidence
Medium dose rate
Neoplasm Recurrence, Local - epidemiology
Neoplasm Staging
Prospective Studies
Radiotherapy
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
Treatment Outcome
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - radiotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: To establish the magnitude of brachytherapy dose reduction required for stage IIB and III carcinoma cervix patients treated by external radiation and medium dose rate (MDR) brachytherapy at a dose rate of 220±10 cGy/h at point A. Materials and methods: In study-I, at the time of MDR brachytherapy application at a dose rate of 220±10 cGy/h at point A, patients received either 3060 cGy, a 12.5% dose reduction (MDR-12.5), or 2450 cGy, a 30% dose reduction (MDR-30), to point A and they were compared to a group of previously treated LDR patients who received 3500 cGy to point A at a dose rate of 55–65 cGy/h. Study-II was a prospective randomized trial and patients received either 2450 cGy, a 30% dose reduction (MDR-II (30)) or 2800 cGy, a 20% dose reduction (MDR-II (20)), at point A. Patients were evaluated for local control of disease and morbidity. Results: In study-I the 5-year actuarial local control rate in the MDR-30 and MDR-12.5 groups was 71.7±10% and 70.5±10%, respectively, compared to 63.4±10% in the LDR group. However, the actuarial morbidity (all grades) in the MDR-12.5 group was 58.5±14% as against 34.9±9% in the LDR group ( P
ISSN:0167-8140
1879-0887
DOI:10.1016/S0167-8140(98)00100-5